Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma
- 1 July 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (7) , 486-491
Abstract
Aim: In vivo pharmacokinetic analysis of [44Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [177Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [177Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. Methods: Pharmacokinetics of [44Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in blood and urine samples, was decay corrected back to the time of injection using the half-life of 44Sc. Afterward, forward decay correction using the half-life of 177Lu was performed, extrapolating the pharmacokinetics of [44Sc]Sc-PSMA-617 to that of [177Lu]Lu-PSMA-617. Source organs residence times and organ-absorbed doses for [177Lu]Lu-PSMA-617 were calculated using OLINDA/EXM software. Bone marrow self-dose was determined with indirect blood-based method, and urinary bladder contents residence time was estimated by trapezoidal approximation. The maximum permissible activity of [177Lu]Lu-PSMA-617 was calculated for each patient considering external beam radiotherapy toxicity limits for radiation absorbed doses to kidneys, bone marrow, salivary glands, and whole body. Results: The predicted mean organ-absorbed doses were highest in the kidneys (0.44 mSv/MBq), followed by the salivary glands (0.23 mSv/MBq). The maximum permissible activity was highly variable among patients; limited by whole body–absorbed dose (1 patient), marrow-absorbed dose (1 patient), and kidney-absorbed dose (3 patients). Conclusions: [44Sc]Sc-PSMA-617 PET/CT imaging is feasible and allows theoretical extrapolation of the pharmacokinetics of [44Sc]Sc-PSMA-617 to that of [177Lu]Lu-PSMA-617, with the intent of predicting normal organ-absorbed doses and maximum permissible activity in patients scheduled for therapy with [177Lu]Lu-PSMA-617.Keywords
This publication has 20 references indexed in Scilit:
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyJournal of Nuclear Medicine, 2016
- Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocksEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor LesionsJournal of Nuclear Medicine, 2015
- Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate CancerJournal of Nuclear Medicine, 2015
- PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusTheranostics, 2015
- Update: Establishing a Clinically Meaningful Predictive Model of Hematologic Toxicity in Nonmyeloablative Targeted Radiotherapy: Practical Aspects and Limitations of Red Marrow DosimetryCancer Biotherapy and Radiopharmaceuticals, 2005
- Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapyActa Oncologica, 2005
- Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood componentsMedical Physics, 2000